These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 29353017

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease.
    Oshi MA, Naeem M, Bae J, Kim J, Lee J, Hasan N, Kim W, Im E, Jung Y, Yoo JW.
    Carbohydr Polym; 2018 Oct 15; 198():434-442. PubMed ID: 30093020
    [Abstract] [Full Text] [Related]

  • 4. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis.
    Naeem M, Bae J, Oshi MA, Kim MS, Moon HR, Lee BL, Im E, Jung Y, Yoo JW.
    Int J Nanomedicine; 2018 Oct 15; 13():1225-1240. PubMed ID: 29535519
    [Abstract] [Full Text] [Related]

  • 5. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles.
    Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW.
    Int J Nanomedicine; 2015 Oct 15; 10():4565-80. PubMed ID: 26213469
    [Abstract] [Full Text] [Related]

  • 6. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis.
    Beloqui A, Coco R, Alhouayek M, Solinís MÁ, Rodríguez-Gascón A, Muccioli GG, Préat V.
    Int J Pharm; 2013 Oct 01; 454(2):775-83. PubMed ID: 23694806
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease.
    Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Préat V.
    Int J Pharm; 2014 Oct 01; 473(1-2):203-12. PubMed ID: 25014369
    [Abstract] [Full Text] [Related]

  • 10. Dual Functional Eudragit® S100/L30D-55 and PLGA Colon-Targeted Nanoparticles of Iridoid Glycoside for Improved Treatment of Induced Ulcerative Colitis.
    Gao C, Yu S, Zhang X, Dang Y, Han DD, Liu X, Han J, Hui M.
    Int J Nanomedicine; 2021 Oct 01; 16():1405-1422. PubMed ID: 33658780
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
    Ali H, Weigmann B, Collnot EM, Khan SA, Windbergs M, Lehr CM.
    Pharm Res; 2016 May 01; 33(5):1085-92. PubMed ID: 26718953
    [Abstract] [Full Text] [Related]

  • 13. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies.
    Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V.
    Int J Pharm; 2013 Jan 02; 440(1):3-12. PubMed ID: 22820482
    [Abstract] [Full Text] [Related]

  • 14. Optimization of budesonide compression-coated tablets for colonic delivery.
    Yehia SA, Elshafeey AH, Sayed I, Shehata AH.
    AAPS PharmSciTech; 2009 Jan 02; 10(1):147-57. PubMed ID: 19199041
    [Abstract] [Full Text] [Related]

  • 15. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
    Du JB, Cheng Y, Teng ZH, Huan ML, Liu M, Cui H, Zhang BL, Zhou SY.
    Mol Pharm; 2016 May 02; 13(5):1711-22. PubMed ID: 26998644
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats.
    Ahmadi F, Varshosaz J, Emami J, Tavakoli N, Minaiyan M, Mahzouni P, Dorkoosh F.
    Drug Deliv; 2011 Feb 02; 18(2):122-30. PubMed ID: 20954795
    [Abstract] [Full Text] [Related]

  • 18. Colon-Targeted Therapy of Tacrolimus (FK506) in the Treatment of Experimentally Induced Colitis.
    Ali AS, Altayari AA, Khan LM, Alharthi SE, Ahmed OA, El-Shitany NA, Ali SS, Saadah OI.
    Pharmacology; 2020 Feb 02; 105(9-10):541-549. PubMed ID: 31940656
    [Abstract] [Full Text] [Related]

  • 19. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis.
    Patel NV, Patel JK, Shah SH, Patel JN.
    Pharmazie; 2011 Feb 02; 66(2):124-9. PubMed ID: 21434575
    [Abstract] [Full Text] [Related]

  • 20. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis.
    Zhou H, Qian H.
    Drug Des Devel Ther; 2018 Feb 02; 12():2601-2609. PubMed ID: 30174414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.